MacroGenics vs Merck: An underdog plans a premier bout with the heavyweight champion of the PD-1 class
Sometime during the fourth quarter of the year, MacroGenics is promising to do something that apparently has never been tried before in the topsy-turvy world of immuno-oncology. They’ll put their experimental PD-1 therapy MGA012, partnered with Incyte, into a study that pits them head-to-head against Keytruda/chemo — the ruling PD-1/(L)1 on the market today — for frontline head and neck cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 73,300+ biopharma pros reading Endpoints daily — and it's free.